MX361413B - Formas cristalinas de un macrólido y usos para las mismas. - Google Patents

Formas cristalinas de un macrólido y usos para las mismas.

Info

Publication number
MX361413B
MX361413B MX2012010895A MX2012010895A MX361413B MX 361413 B MX361413 B MX 361413B MX 2012010895 A MX2012010895 A MX 2012010895A MX 2012010895 A MX2012010895 A MX 2012010895A MX 361413 B MX361413 B MX 361413B
Authority
MX
Mexico
Prior art keywords
crystalline forms
macrolide
uses therefor
therefor
preparing
Prior art date
Application number
MX2012010895A
Other languages
English (en)
Other versions
MX2012010895A (es
Inventor
E Pereira David
Original Assignee
Cempra Pharmaceuticals Inc Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44673574&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX361413(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cempra Pharmaceuticals Inc Star filed Critical Cempra Pharmaceuticals Inc Star
Publication of MX2012010895A publication Critical patent/MX2012010895A/es
Publication of MX361413B publication Critical patent/MX361413B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08Hetero rings containing eight or more ring members, e.g. erythromycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/04Nitro compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Abstract

Se describen en la presente nuevas formas cristalinas de compuestos macrólidos, y composiciones farmacéuticas de las mismas. Además, se describen en la presente procesos para preparar las formas cristalinas.
MX2012010895A 2010-03-22 2011-03-22 Formas cristalinas de un macrólido y usos para las mismas. MX361413B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31606310P 2010-03-22 2010-03-22
PCT/US2011/029424 WO2011119604A1 (en) 2010-03-22 2011-03-22 Crystalline forms of a macrolide, and uses therefor

Publications (2)

Publication Number Publication Date
MX2012010895A MX2012010895A (es) 2013-02-15
MX361413B true MX361413B (es) 2018-12-05

Family

ID=44673574

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010895A MX361413B (es) 2010-03-22 2011-03-22 Formas cristalinas de un macrólido y usos para las mismas.

Country Status (20)

Country Link
US (4) US8975386B2 (es)
EP (2) EP2550286B1 (es)
JP (4) JP5711352B2 (es)
KR (2) KR20180101643A (es)
CN (2) CN103080122A (es)
AU (2) AU2011232627B2 (es)
BR (1) BR112012023950A2 (es)
CA (1) CA2793884C (es)
DK (1) DK2550286T3 (es)
ES (1) ES2564097T3 (es)
HK (1) HK1177937A1 (es)
HR (1) HRP20160168T1 (es)
IL (1) IL222018B (es)
MX (1) MX361413B (es)
MY (1) MY162411A (es)
NZ (1) NZ602544A (es)
PL (1) PL2550286T3 (es)
RU (1) RU2650883C2 (es)
SI (1) SI2550286T1 (es)
WO (1) WO2011119604A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1638549A4 (en) 2003-03-10 2011-06-15 Optimer Pharmaceuticals Inc NEW ANTIBACTERIAL AGENTS
EP2214484A4 (en) 2007-10-25 2013-01-02 Cempra Pharmaceuticals Inc PROCESS FOR PREPARING ANTIBACTERIAL MAKROLIDE AGENTS
US8796232B2 (en) 2008-10-24 2014-08-05 Cempra Pharmaceuticals, Inc. Methods for treating resistant diseases using triazole containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
AU2010292010B2 (en) 2009-09-10 2016-01-07 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and MAC diseases
CN103080122A (zh) * 2010-03-22 2013-05-01 森普拉制药公司 大环内脂的结晶形式及其用途
US9051346B2 (en) 2010-05-20 2015-06-09 Cempra Pharmaceuticals, Inc. Process for preparing triazole-containing ketolide antibiotics
JP6042334B2 (ja) 2010-09-10 2016-12-14 センプラ ファーマシューティカルズ,インコーポレイテッド 疾患治療のための水素結合形成フルオロケトライド
CN104470527B (zh) 2012-03-27 2019-05-28 森普拉制药公司 用于施用大环内酯抗生素的肠胃外制剂
WO2014152326A1 (en) 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
US9751908B2 (en) 2013-03-15 2017-09-05 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
CA3130061A1 (en) 2013-04-04 2014-10-09 President And Fellows Of Harvard College Macrolides and methods of their preparation and use
AU2015301154A1 (en) * 2014-08-05 2017-02-23 Cempra Pharmaceuticals, Inc. Powder oral suspension formulations of antibacterial agents
CN104151382B (zh) * 2014-08-08 2016-09-14 广东东阳光药业有限公司 一种固态大环内酯的晶型
CN104311611B (zh) * 2014-08-13 2017-01-18 广东东阳光药业有限公司 一种制备固态大环内酯的方法
JP2017531663A (ja) 2014-10-08 2017-10-26 プレジデント アンド フェローズ オブ ハーバード カレッジ 14員ケトライドならびにそれらの調製および使用の方法
CA2980315A1 (en) 2015-03-25 2016-09-29 President And Fellows Of Harvard College Macrolides with modified desosamine sugars and uses thereof
WO2017061431A1 (ja) * 2015-10-05 2017-04-13 富山化学工業株式会社 ソリスロマイシンを含む錠剤
EP3190122A1 (en) * 2016-01-08 2017-07-12 LEK Pharmaceuticals d.d. A novel synthetic pathway towards solithromycin and purification thereof
WO2018045294A1 (en) * 2016-09-02 2018-03-08 Cempra Pharmaceuticals, Inc. Processes for preparing fluoroketolides
IL293115A (en) * 2019-12-02 2022-07-01 Aliquantumrx Inc Salts and polymorphs of cethromycin for the treatment of disease Salts and polymorphs of cethromycin

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4742049A (en) 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
IL114589A (en) 1990-11-21 1999-12-22 Roussel Uclaf Intermediates for the preparation of the history of erythromycin
US5985844A (en) 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2697524B1 (fr) 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2718450B1 (fr) 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
FR2739620B1 (fr) 1995-10-09 1997-12-19 Roussel Uclaf Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
FR2742757B1 (fr) 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2745290B1 (fr) 1996-02-28 1998-04-03 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
KR100523679B1 (ko) 1996-09-04 2005-10-26 아보트 러보러터리즈 항균 활성을 지닌 6-o-치환된 케톨라이드
US6407074B1 (en) 1997-06-11 2002-06-18 Pfizer Inc C-4″-substituted macrolide derivatives
EA199901016A1 (ru) 1997-06-11 2000-06-26 Пфайзер Продактс Инк. 9-оксим-производные эритромицина
HN1998000086A (es) 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
HN1998000159A (es) 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
IL135792A0 (en) 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
FR2777282B1 (fr) 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
FR2785612A1 (fr) 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2786188B1 (fr) 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
KR100317907B1 (ko) * 1998-11-24 2001-12-24 김 완 주 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법
ES2273964T3 (es) 1998-12-10 2007-05-16 Pfizer Products Inc. Antibioticos de carbamato y carbazato cetolida.
ID30233A (id) 1999-01-27 2001-11-15 Pfizer Prod Inc Antibiotika ketolida
CA2411293A1 (en) 1999-01-28 2000-07-28 Pfizer Products Inc. Novel azalides and methods of making same
WO2000062783A2 (en) 1999-04-16 2000-10-26 Ortho-Mcneil Pharmaceutical, Inc. Ketolide antibacterials
ATE340183T1 (de) 1999-04-16 2006-10-15 Kosan Biosciences Inc Antiinfektiöse makrolidderivate
US6420535B1 (en) 1999-06-07 2002-07-16 Abbott Laboratories 6-O-carbamate ketolide derivatives
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
AU6183700A (en) 1999-08-06 2001-03-05 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
KR100336447B1 (ko) 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
JP2001261694A (ja) 2000-03-06 2001-09-26 Pfizer Prod Inc ケトライド抗生物質
DE60122791T2 (de) 2000-03-15 2007-10-04 Hanmi Pharm. Co., Ltd. Verfahren zur Herstellung von Clarythromycin mit nicht pharmazeutischer Qualität
US20020115621A1 (en) 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
GB0031312D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Macrolides
CA2447600C (en) 2001-05-18 2015-10-20 Chiron Corporation Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
US6756359B2 (en) 2001-07-03 2004-06-29 Chiron Corporation C12 modified erythromycin macrolides and ketolides having antibacterial activity
US20030176327A1 (en) 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
US20040019012A1 (en) 2002-02-22 2004-01-29 Singh Satish K. Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
AU2003240482B2 (en) 2002-05-30 2009-03-12 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
US7091196B2 (en) 2002-09-26 2006-08-15 Rib-X Pharmaceuticals, Inc. Bifunctional heterocyclic compounds and methods of making and using same
ITMI20022292A1 (it) 2002-10-29 2004-04-30 Zambon Spa 9a-azalidi ad attivita' antiinfiammatoria.
EP1638549A4 (en) * 2003-03-10 2011-06-15 Optimer Pharmaceuticals Inc NEW ANTIBACTERIAL AGENTS
US7163924B2 (en) 2003-04-25 2007-01-16 Chiron Corporation Ketolide derivatives
WO2005007143A2 (en) 2003-07-14 2005-01-27 The Board Of Trustees Of The University Of Illinois Use of makrolides and ketolides for the treatment of tuberculosis
US7457520B2 (en) 2003-07-24 2008-11-25 Time Warner Cable, Inc. Technique for providing a virtual digital video recorder service through a communications network
US20060116336A1 (en) 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
AU2005238313A1 (en) 2004-04-28 2005-11-10 Alembic Limited Process for the preparation of telithromycin
BRPI0513903A (pt) 2004-07-28 2008-05-20 Ranbaxy Lab Ltd derivados de cetolìdeos úteis como agentes antimicrobianos, seus processos de preparação e composições farmacêuticas compreendendo os mesmos
AU2005317735B2 (en) * 2004-12-21 2009-06-04 Pfizer Products Inc. Macrolides
EP1835921B1 (en) 2005-01-14 2010-08-18 GlaxoSmithKline istrazivacki centar Zagreb d.o.o. 9a-carbamoyl-y-aminopropyl- and 9a-thiocarbamoyl-y-aminopropyl-azalides with antimalarial activity
WO2007039914A2 (en) 2005-10-06 2007-04-12 Alembic Limited Novel polymorphs of telithromycin
WO2007059307A2 (en) * 2005-11-15 2007-05-24 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous forms of telithromycin
WO2007060627A2 (en) 2005-11-23 2007-05-31 Ranbaxy Laboratories Limited Use of macrolide derivatives for treating acne
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
CN101129383B (zh) 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
US7742562B2 (en) * 2007-06-27 2010-06-22 Accuray Incorporated Lower-torso assembly of a treatment couch useable in an X-ray environment
EP2220104A1 (en) 2007-10-25 2010-08-25 Sandoz AG Process for the production of telithromycin
EP2214484A4 (en) * 2007-10-25 2013-01-02 Cempra Pharmaceuticals Inc PROCESS FOR PREPARING ANTIBACTERIAL MAKROLIDE AGENTS
US8796232B2 (en) * 2008-10-24 2014-08-05 Cempra Pharmaceuticals, Inc. Methods for treating resistant diseases using triazole containing macrolides
JP5890785B2 (ja) 2010-03-10 2016-03-22 センプラ ファーマシューティカルズ,インコーポレイテッド マクロライド抗生物質の非経口製剤
CN103080122A (zh) 2010-03-22 2013-05-01 森普拉制药公司 大环内脂的结晶形式及其用途

Also Published As

Publication number Publication date
WO2011119604A1 (en) 2011-09-29
JP2020002168A (ja) 2020-01-09
AU2011232627B2 (en) 2016-03-17
NZ602544A (en) 2014-11-28
JP6121387B2 (ja) 2017-04-26
US20130018008A1 (en) 2013-01-17
EP2550286A1 (en) 2013-01-30
JP2013522367A (ja) 2013-06-13
PL2550286T3 (pl) 2016-07-29
ES2564097T3 (es) 2016-03-17
MX2012010895A (es) 2013-02-15
US20130252915A1 (en) 2013-09-26
HRP20160168T1 (hr) 2016-03-25
US20190040096A1 (en) 2019-02-07
CA2793884C (en) 2019-09-10
CA2793884A1 (en) 2011-09-29
EP2550286B1 (en) 2015-12-09
US8759500B2 (en) 2014-06-24
KR102006200B1 (ko) 2019-08-01
CN108570083A (zh) 2018-09-25
EP2550286A4 (en) 2013-10-02
JP5711352B2 (ja) 2015-04-30
RU2012144614A (ru) 2014-04-27
KR20180101643A (ko) 2018-09-12
US8975386B2 (en) 2015-03-10
EP3009442B1 (en) 2019-06-19
SI2550286T1 (sl) 2016-04-29
AU2016203986B2 (en) 2016-10-06
MY162411A (en) 2017-06-15
RU2650883C2 (ru) 2018-04-18
KR20130056226A (ko) 2013-05-29
BR112012023950A2 (pt) 2016-07-05
AU2016203986A1 (en) 2016-06-30
IL222018B (en) 2019-05-30
EP3009442A1 (en) 2016-04-20
US20160244472A1 (en) 2016-08-25
DK2550286T3 (en) 2016-02-29
AU2011232627A1 (en) 2012-10-18
JP2017081953A (ja) 2017-05-18
CN103080122A (zh) 2013-05-01
JP2015063536A (ja) 2015-04-09
HK1177937A1 (en) 2013-08-30

Similar Documents

Publication Publication Date Title
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
MX2013012542A (es) Compuestos de amida y aplicacion farmaceutica para el mismo.
WO2011130615A3 (en) Preparation of lacosamide
EP2746283A4 (en) PYRIMIDOPYRIMIDONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES
IL216826A0 (en) Pyridil-triazine derivatives, compositions comprising the same and processes for producing the same
IL232914A0 (en) New Azetidine histories, pharmaceutical preparations and their uses
MX2012007507A (es) Compuestos de heteroarilo y usos de los mismos.
PT2531492T (pt) Derivados 1,2,4-triazina4-amina
ZA201208198B (en) Picolinamide and pyrimidine-4-carboxamine compounds, process for preparing and pharmaceutical composition comprising the same
CA2830549C (en) Methods and compositions for preparing noribogaine from voacangine
TW201144301A (en) Processes for preparing linezolid
HUE037747T2 (hu) Nanostrukturált aprepirant készítmények, eljárások azok elõállítására és az azokat tartalmazó gyógyászati készítmények
EP2702054A4 (en) NOVEL BISAMINOQUINOLINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS PREPARED THEREFROM, AND USE THEREOF
WO2010117738A3 (en) Solid state forms of sitagliptin salts
ZA201301463B (en) Pharmaceutical compositions for calonolides,their derivatives and analogues,and process for producing the same
WO2012068441A3 (en) Intedanib salts and solid state forms thereof
ZA201108292B (en) New compounds,pharmaceutical composition and methods relating thereto
PL2531505T3 (pl) Sposób wytwarzania kompleksów 3,7-diaza-bicyklo[3.3.1]nonanu z metalami
AP2011005935A0 (en) New Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions comprising them.
IN2012DN02793A (es)
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
PT2504331E (pt) Composto, novas formas desse composto, composições farmacêuticas desse composto e métodos de preparação e utilização
EP2784061A4 (en) ACYLHYDRACO AND OXADIAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF
EP2742946A4 (en) PROCESS FOR THE PRODUCTION OF PYROSTEGIA VENUSTA DERIVATIVES, PYROSTEGIA VENUSTA DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
AP2012006645A0 (en) Pharmaceutical compositions comprising paracetamoland process for preparing the same

Legal Events

Date Code Title Description
FG Grant or registration